Compare MGTX & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGTX | AZTA |
|---|---|---|
| Founded | 2015 | 1978 |
| Country | United States | United States |
| Employees | N/A | 2900 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 909.1M | 738.4M |
| IPO Year | 2018 | 1996 |
| Metric | MGTX | AZTA |
|---|---|---|
| Price | $9.63 | $18.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $24.57 | ★ $40.60 |
| AVG Volume (30 Days) | 686.8K | ★ 1.3M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.02 | ★ 60.52 |
| EPS | ★ N/A | N/A |
| Revenue | $81,391,000.00 | ★ $593,821,000.00 |
| Revenue This Year | $141.38 | $6.99 |
| Revenue Next Year | N/A | $5.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 144.57 | N/A |
| 52 Week Low | $5.02 | $15.93 |
| 52 Week High | $11.85 | $41.73 |
| Indicator | MGTX | AZTA |
|---|---|---|
| Relative Strength Index (RSI) | 51.51 | 41.41 |
| Support Level | $7.13 | N/A |
| Resistance Level | $9.65 | $32.32 |
| Average True Range (ATR) | 0.48 | 1.16 |
| MACD | -0.08 | -0.30 |
| Stochastic Oscillator | 49.22 | 27.06 |
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.